With two deals, Evonik Industries is pushing further into the medical materials market. The specialty chemical maker has acquired from Canada’s Interface Biologics surface-modification technology based on low-molecular-weight fluorooligomers that enhance medical devices’ biocompatibility. Separately, Evonik has invested in the 3-D printing start-up Meditool. The Shanghai-based firm—representing Evonik Venture Capital’s first direct investment in China—makes implants for neuro and spine surgery.
Date: September 10, 2019
Source: C&EN